Effettuare il login Iscriviti gratis

Financière de Tubize SA Ret. sull'equità

Cos'è Ret. sull'equità di Financière de Tubize SA?

Ret. sull'equità di Financière de Tubize SA è 9.88%

Qual è la definizione di Ret. sull'equità?



Il rendimento del capitale netto è una misura della redditività di un'impresa in relazione al valore contabile del capitale azionario. Viene calcolato dividendo l'utile netto dell'anno fiscale per il capitale azionario totale.

The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.

Ret. sull'equità di aziende nel Health Care settore su EURONEXT rispetto a Financière de Tubize SA

Cosa fa Financière de Tubize SA?

Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.

Aziende con ret. sull'equità simili a Financière de Tubize SA